The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

Described herein are modified monoterpene TRPM8 activating compounds. In particular, provided herein are compounds that affect the function of ion channels in a cell, and are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth, such as cancers.

Described herein are modified monoterpene TRPM8 activating compounds. In particular, provided herein are compounds that affect the function of ion channels in a cell, and are useful as therapeutic agents or with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and conditions including inflammatory eye diseases such as uveitis, cardiovascular diseases, inflammatory diseases, and diseases characterized by abnormal growth, such as cancers.

The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

A process for preparing a compound of Formula I is disclosed, comprising the steps: ##STR00001##
wherein: R.sup.1 is halo; R.sup.2 is halo; R.sup.3 is (C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkyl optionally substituted with heterocycloalkyl; R.sup.4 is (C.sub.1-C.sub.6)alkyl; and Q is CH or N;
comprising: (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent; (b) adding ##STR00002##
and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and ##STR00003## (c) coupling a compound of Formula A with an amine of Formula B to form a compound of Formula I. ##STR00004##

A process for preparing a compound of Formula I is disclosed, comprising the steps: ##STR00001##
wherein: R.sup.1 is halo; R.sup.2 is halo; R.sup.3 is (C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkyl optionally substituted with heterocycloalkyl; R.sup.4 is (C.sub.1-C.sub.6)alkyl; and Q is CH or N;
comprising: (a) contacting 1,1-cyclopropane dicarboxylic acid with thionyl chloride in a polar aprotic solvent; (b) adding ##STR00002##
and a tertiary amine base to the mixture of step (a) to form a compound of Formula A; and ##STR00003## (c) coupling a compound of Formula A with an amine of Formula B to form a compound of Formula I. ##STR00004##

The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

The present disclosure relates to methods and compounds for liquid phase oligonucleotide synthesis employing the use of small molecules with lipophilic groups. Methods for making an oligonucleotide by liquid phase oligonucleotide synthesis using the compounds described herein are also provided.

The present disclosure relates to methods and compounds for liquid phase oligonucleotide synthesis employing the use of small molecules with lipophilic groups. Methods for making an oligonucleotide by liquid phase oligonucleotide synthesis using the compounds described herein are also provided.